P4 Does uptake of 99mTc sestamibi indicate tumour grade in breast cancer?

2005 ◽  
Vol 26 (1) ◽  
pp. 78
Author(s):  
E. McCauley ◽  
A. Mackie ◽  
P. Cadigan ◽  
A.I.M. Cook
2004 ◽  
Vol 25 (4) ◽  
pp. 401
Author(s):  
C. Marshall ◽  
F.J. Bissett ◽  
M.A. Lax ◽  
J. Eremin ◽  
M. El-Sheemy ◽  
...  

2001 ◽  
Vol 28 (6) ◽  
pp. 711-720 ◽  
Author(s):  
Reinhold Tiling ◽  
Rainer Linke ◽  
Michael Untch ◽  
Almuth Richter ◽  
Siegrid Fieber ◽  
...  

2008 ◽  
Vol 2 ◽  
pp. CMO.S474
Author(s):  
Isaac D. Gukas ◽  
Anne C. Girling ◽  
Barnabas M. Mandong ◽  
Wendy Prime ◽  
Barbara A. Jennings ◽  
...  

Background Some studies have suggested that breast cancer in black women is more aggressive than in white women. This study's aim was to look for evidence of differences in tumour biology between the two cohorts. Methods This study compared the stage, grade and pathological expression of five immunohistochemical markers (oestrogen receptor [ER], progesterone receptor [PR], ERBB2, P53 and cyclin D1 [CCND1]) in tumour biopsies from age-matched cohorts of patients from Nigeria and England. Sixty-eight suitable samples from Nigerian (n = 34) and British (n = 34) breast cancer patients were retrieved from histology tissue banks. Results There were significant differences between the two cohorts in the expression of ER and CCND1; and stark differences in the clinical stage at presentation. But no significant differences were observed for tumour grade. Conclusion There was a significantly, low ER expression in the Nigerian cases which also predicts a poor response to hormonal therapy as well as a poorer prognosis. Differences in clinical stage at presentation will most likely influence prognosis between Nigerian and British women with breast cancer.


Author(s):  
Maha Abdel Hadi ◽  
Afnan Al-Muhanna ◽  
Lina Abu Arida ◽  
Dina Lutfi

Abstract Background: Intraoperative radiotherapy (IORT) has gained popularity over recent years due to its impact on shortening the radiotherapy treatment time for early breast cancer. It has certainly proven effective as an exclusive treatment or when combined with whole breast irradiation (WBIR). Seroma is a common non-life-threatening complication that may delay treatment and impose challenges on radiological diagnostic follow-up. Aim: To review and compare the occurrence of seroma in patients who received exclusive IORT or when combined with WBIR and to outline the diagnostic challenges encountered during radiological follow-up. Materials and methods: Based on strict selection criteria, all eligible patients who received IORT ± WBIR treatment between 2012 and 2019 in a university hospital setting were included. Demographic data, histological diagnosis, tumour size, tumour grade, lymphovascular invasion, nodal status, receptor status, treatment with neoadjuvant hormonal chemotherapy, applicator size, dose used, duration of radiotherapy treatment, timing of seroma development and duration of seroma were documented. Both clinical and radiological follow-up were exercised in all patients. Results: The total number of patients treated with breast conserving surgery (BCS) and IORT was 86. Age ranged between 31 and 75 years with the median age of 51 years. Patients treated exclusively with IORT were 39 (45%) while those who received the IORT as a boost were 47 (55%). Seroma was observed in 39(45%) of both IORT and IORT\WBIR patients. Those included 15(38%) of the exclusive IORT treated patients and 24 (62%) of those treated as a boost. Duration of asymptomatic seroma ranged from 6 months to 6 years. Repeated aspiration was performed in 2 (5%) patients. Postoperative seroma occurred independent of age histological diagnosis, tumour size, tumour grade, lymphovascular invasion, nodal status, receptor status, treatment with neoadjuvant hormonal\chemotherapy, applicator size, dose used or duration of radiotherapy treatment. All reviewed patients have shown increased risk of developing seroma; however, an increased incidence of seroma in the IORT + WBIR treated patients was higher than those who received exclusive IORT treatment. Conclusion: Postoperative seroma is a common non-life-threatening entity that occasionally may lead to delay in the subsequent treatment plan. IORT is a safe modality with many benefits; however, it may increase the risk of seroma formation independent of the clinical parameters. Promoting the expertise in post IORT breast imaging aids in overcoming diagnostic challenges.


2009 ◽  
Vol 124 (9) ◽  
pp. 2088-2097 ◽  
Author(s):  
Fiona Lanigan ◽  
Eadaoin McKiernan ◽  
Donal J. Brennan ◽  
Shauna Hegarty ◽  
Robert C. Millikan ◽  
...  

Author(s):  
Mahshid Hatami ◽  
Saeid Doaei ◽  
Maryam Gholamalizadeh ◽  
Seyed Alireza Mosavi Jarrahi ◽  
Faezeh Mirsafa ◽  
...  

2006 ◽  
Vol 20 (1) ◽  
pp. 29-34 ◽  
Author(s):  
Seigo Kinuya ◽  
Jingming Bai ◽  
Kazuhiro Shiba ◽  
Kunihiko Yokoyama ◽  
Hirofumi Mori ◽  
...  

The Breast ◽  
1997 ◽  
Vol 6 (5) ◽  
pp. 326
Author(s):  
R. Thomas ◽  
A. Ciarmiello ◽  
S. Del Vecchio ◽  
G. Botti ◽  
G. Cortino ◽  
...  

2006 ◽  
Vol 12 (3) ◽  
pp. 202-207 ◽  
Author(s):  
Giuliano Mendes Duarte ◽  
Cesar Cabello dos Santos ◽  
Renato Zocchio Torresan ◽  
Marcelo Alvarenga ◽  
Gilliat H. Q. Telles ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document